41
Participants
Start Date
August 12, 2016
Primary Completion Date
November 30, 2018
Study Completion Date
November 30, 2018
TAK-659
TAK-659 Tablets.
Nivolumab
Nivolumab intravenous infusion.
Massachusetts General, Boston
Roswell Park, Buffalo
Fox Chase, Philadelphia
Istituto di Ricovero e Cura a Carattere Scientifico - Istituto Clinico Humanitas (Humanitas Research, Milan
Ospedale San Raffaele, Milan
US Oncology, Fairfax
Hospital General Universitario Gregorio Maranon, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Clinico Universitario Virgen de la Victoria, Málaga
Emory, Atlanta
Consejo Superior de Investigaciones Cientificas (CSIC) - Centro de Investigacion del Cancer (CIC), Salamanca
Vanderbilt, Nashville
Azienda Ospedaliero - Universitaria di Modena Policlinico, Modena
Hospital Universitario La Fe, Valencia
Hospital Clinico Universitario de Valencia (CHUV), Valencia
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) S.r.l, Meldola
Barbara Ann Karmanos, Detroit
Azienda Ospedaliera Universitaria Senese - Policlinico Santa Maria Alle Scotte, Siena
Mary Crowley Research Centers, Dallas
UCSD, La Jolla
The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital - Northern Centre for Canc, Newcastle upon Tyne
University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton
Lead Sponsor
Calithera Biosciences, Inc
INDUSTRY